What is PHIGENIX?
PHIGENIX, Inc. is a prominent entity in personalized healthcare, focusing on advanced cancer diagnostics and the development of targeted therapies. The company leverages state-of-the-art technology to create diagnostic tests for prostate and breast cancer, identifying patients who would most benefit from specific treatment regimens. Their pioneering work extends to novel approaches in early cancer detection and the creation of a cancer vaccine utilizing Human Beta Defensin-1 mRNA to target cancer cells. PHIGENIX's innovative foundation is supported by a substantial intellectual property portfolio, comprising over 100 patents and pending applications in personalized medicine.
How much funding has PHIGENIX raised?
PHIGENIX has raised a total of $856K across 2 funding rounds:
Private Equity
$842K
Debt
$14K
Private Equity (2014): $842K, investors not publicly disclosed
Debt (2021): $14K led by PPP
What's next for PHIGENIX?
The recent infusion of moderate growth capital, alongside the company's substantial total funding, positions PHIGENIX for strategic expansion and further development of its innovative cancer diagnostics and therapies. This investment is expected to accelerate the advancement of their patented technologies, potentially bringing their cancer vaccine closer to clinical application and enhancing their diagnostic test offerings. The company's focus on personalized medicine and its robust patent portfolio suggest a trajectory aimed at capturing a significant share of the evolving oncology market, with future growth likely driven by clinical trial progress and strategic partnerships.
See full PHIGENIX company page
